Solid Biosciences to Host First Quarter 2021 Financial Results and Business Update Call on May 14, 2021
Solid Biosciences (Nasdaq: SLDB) announced it will release its first quarter 2021 financial results before the market opens on May 14, 2021.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Solid Biosciences (Nasdaq: SLDB) announced it will release its first quarter 2021 financial results before the market opens on May 14, 2021. A conference call will be held at 8:30 a.m. ET to discuss the financial results and recent business updates. The event can be accessed via a live webcast on the company's website, with an archived version available afterward. Solid Biosciences focuses on developing therapies for Duchenne muscular dystrophy, primarily through its lead gene therapy candidate, SGT-001.
Positive
- Scheduled release of Q1 2021 financial results indicates transparency and communication with investors.
Negative
- None.
Details
News Market Reaction – SLDB
The recorded move for SLDB in the trading session of this news was +0.22%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., May 11, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that it will release first quarter 2021 financial results before the market opens on Friday, May 14, 2021. Management will host a conference call on the same date beginning at 8:30 a.m. ET to discuss the Company’s financial results and recent business developments.
A live webcast of the call will be available on the Company's website at www.solidbio.com under the “News & Events” tab in the Investor Relations section, or by clicking here. Participants may also access the call, by dialing 866-763-0341 for domestic callers or 703-871-3818 for international callers, referencing conference ID# 4772539.
The archived webcast will be available in the “News and Events” section of the Company's website.
About Solid Biosciences
Solid Biosciences is a life sciences company focused on advancing transformative treatments to improve the lives of patients living with Duchenne. Disease-focused and founded by a family directly impacted by Duchenne, our mandate is simple yet comprehensive – work to address the disease at its core by correcting the underlying mutation that causes Duchenne with our lead gene therapy candidate, SGT-001. For more information, please visit www.solidbio.com.
Investor Contact:
David Carey
FINN Partners
212-867-1768
David.Carey@finnpartners.com
Media Contact:
Erich Sandoval
FINN Partners
917-497-2867
Erich.Sandoval@finnpartners.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.